Relmada Therapeutics (RLMD) Accumulated Expenses (2014 - 2026)

Relmada Therapeutics (RLMD) has 13 years of Accumulated Expenses data on file, last reported at $7.2 million in Q1 2026.

• On a quarterly basis, Accumulated Expenses rose 179.0% year-over-year to $7.2 million in Q1 2026; TTM through Mar 2026 was $7.2 million, a 179.0% increase from a year earlier, with the FY2025 full-year figure at $535500.0, down 26.87% from the prior year.
• Accumulated Expenses for Q1 2026 stood at $7.2 million, up from $535500.0 in the prior quarter.
• Over the last five years, Accumulated Expenses for RLMD reached as high as $11.4 million in Q2 2022 and fell as low as $67100.0 in Q3 2023.
• Historically, Accumulated Expenses has averaged $4.2 million across 5 years, with a median of $5.4 million in 2024.
• Across the five-year window, Accumulated Expenses jumped 14797.21% in 2022 and tumbled 99.35% in 2023, its largest moves.
• Year by year, Accumulated Expenses stood at $7.2 million in 2022, then tumbled by 94.84% to $372200.0 in 2023, then surged by 96.75% to $732300.0 in 2024, then dropped by 26.87% to $535500.0 in 2025, then surged by 1237.11% to $7.2 million in 2026.
• Per Business Quant data, the three most recent Accumulated Expenses figures were $7.2 million in Q1 2026, $535500.0 in Q4 2025, and $532600.0 in Q3 2025.